Search for content, post, videos

Ferring appoints Jan Lundberg to its Group Board

Jan Lundberg

Ferring Pharmaceuticals has announced that Jan Lundberg has been appointed to the Ferring Group Board, effective January 2021, as a non-executive director and Chairman of the Research and Development Committee, following the retirement of John Patterson.

“I am delighted to welcome Jan to the Ferring Group Board and am confident that, with his strong scientific and medical background, Jan will provide significant value to Ferring and our patients as we move into our next phase of growth through innovation,” says Frederik Paulsen, Chairman of the Ferring Board of Directors.

18 years’ leadership experience with global organizations

Dr. Lundberg has 18 years’ leadership experience with global organizations such as AstraZeneca and Eli Lilly and supervised the discovery and development of more than 200 candidate drugs leading to 25 approved products across multiple therapeutic areas. He has also served on the boards of several biotechnology companies and on governmental committees in the EU and USA.

Dr. Lundberg holds M.D. and Ph.D. degrees, and before joining industry was Professor of Pharmacology at the Karolinska Institute in Sweden.

Read more: Jan Lundberg: The long view of R&D at Eli Lilly